Table 5

Impact of vitamin E on inflammation score, ballooning score, fibrosis score and histological improvement

Author and yearOutcomes with respect to control and intervention group
Inflammation scoreBallooning scoreFibrosis scoreHistological improvement
InterventionControlP valueInterventionControlP valueInterventionControlP valueInterventionControlP value
Harrison et al, 200312 **NRNRNRNR−0.5−0.30.002NRNRNR
Vajro et al , 200418 NRNRNRNRNRNRNRNRNR**NR
Nobili et al , 200616 NRNRNRNRNRNR
Nobili et al , 200817 0−10.72−10.1110.6−2−20.06
Sanyal et al, 201015 −0.972−0.560.02−0.65−0.3770.01−0.615−0.4960.24−0.912−2.1930.001
Lavine et al , 20116 −0.352−0.340.89−0.22−0.080.02−0.216−0.2280.7−1.2−0.5060.006
Foster et al , 201113 NRNRNRNRNRNRNRNRNRNRNRNR
Hoofnagle et al , 201314 −1.1−0.5Vitamin E=<0.001
Placebo=0.14
−0.8−0.5Vitamin E=0.01
Placebo=0.42
−0.5−0.8Vitamin E=0.34
Placebo=0.04
−4.12−1.58Vitamin E=0.07
Placebo=0.03
Aller et al , 20151 NRNRNRNRNRNR**NRNRNRNR
  • (−) Improvement in the outcome (mean response value − mean baseline value).

  • *Non-significant improvement.

  • †Inflammation was present in 77 children. Hepatocyte ballooning was present in 46 patients. Increased fibrosis was noted in 54 but mostly of mild (stage 1) severity, with only five children showing septal fibrosis (stage3).

  • NR, not reported.